Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Fujian Ribio Technology Co. Ltd. manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single active matter is assigned to 1 distinct examiner and 1 distinct art unit. The portfolio's current USPTO engagement is concentrated on a single biotechnological innovation. This allows for a focused prosecution strategy without the need to manage multiple examiners or art units.
KRISHNAN, GANAPATHY is the busiest examiner for the company, handling 1 pending office action. This 1 examiner oversees the entirety of the company's pending workload. Prosecution efforts are therefore focused on the specific requirements and examination style of this single individual within their assigned art unit. Practitioners should prioritize understanding the specific technical expectations of KRISHNAN, GANAPATHY.
Because there is only 1 pending office action, the company's patent trajectory in the Biotechnology & Pharmaceuticals sector is currently tied to this single matter. The procedural rules of the 1 distinct art unit will govern the timeline and requirements for the application. Practitioners should ensure that all arguments are aligned with the specific standards of this art unit to maximize the chances of a favorable outcome for the company.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KRISHNAN, GANAPATHY | 1 | 52.7% | +1.3% |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18560414 | METHOD FOR PREPARING ANTI-HIV DRUG ISLATRAVIR | KRISHNAN, GANAPATHY | 1693 | §103 | Final Rejection | — | Pending | Nov 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFujian Ribio Technology Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ganapathy Krishnan has the most, with 1 of Fujian Ribio Technology Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
